2019
Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial
Krishnan-Sarin S, O’Malley S, Franco N, Cavallo DA, Tetrault JM, Shi J, Gueorguieva R, Pittman B, Krystal JH. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Neuropsychopharmacology 2019, 45: 319-326. PMID: 31590179, PMCID: PMC6901445, DOI: 10.1038/s41386-019-0536-z.Peer-Reviewed Original ResearchConceptsAlcohol drinking behaviorFirst treatment periodTreatment periodNumber of drinksCrossover trialDrinking behaviorEfficacy of naltrexoneOpioid antagonist naltrexoneNMDA antagonist memantinePositive family historyDay treatment periodSelf-administration periodAlcohol-induced stimulationAd lib accessMemantine treatmentAntagonist naltrexoneOpioid systemFamily historyNTXPriming drinkMemantineNaltrexoneAlcohol cravingHeavy drinkersAlcohol dependence
2006
Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism
Krystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, Belger A, D'Souza DC. Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism. Neuropsychopharmacology 2006, 31: 1793-1800. PMID: 16395307, DOI: 10.1038/sj.npp.1300994.Peer-Reviewed Original ResearchConceptsNMDA glutamate receptorsNMDA receptor antagonismKetamine doseReceptor antagonismGlutamate receptorsKetamine effectsProtective effectPlacebo-controlled human laboratory studyOpiate receptor antagonismEfficacy of naltrexoneDose-related fashionNMDA receptor antagonist effectsReceptor antagonist effectsTotal PANSS scoreHuman laboratory studiesPharmacotherapy of alcoholismTreatment of alcoholismHealthy human subjectsHigher ketamine doseNegative Syndrome ScaleLower ketamine doseSignificant behavioral effectsSubanesthetic dosePANSS scoresEthanol drink
2005
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 2005, 184: 254-256. PMID: 16374600, DOI: 10.1007/s00213-005-0246-6.Peer-Reviewed Original ResearchConceptsRefractory obsessive-compulsive disorderObsessive-compulsive disorderN-acetylcysteineGlutamatergic neurotransmissionUse of NACYale-Brown Obsessive Compulsive Scale scoresSerotonin reuptake inhibitorsEfficacy of augmentationRecent clinical reportsTreatment of OCDCompulsive Scale scoresNAC augmentationGlutamatergic dysfunctionReuptake inhibitorsLabel usePsychiatric disordersClinical reportsScale scoreModulating agentsDisordersSingle casePatientsFluvoxamineNeurotransmissionOCD symptomsγ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation
D’Souza D, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS, Boutros NN, Cooper T, Seibyl J, Krystal JH. γ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation. Biological Psychiatry 2005, 59: 128-137. PMID: 16140281, DOI: 10.1016/j.biopsych.2005.06.020.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnxietyCross-Over StudiesDissociative DisordersDouble-Blind MethodDrug SynergismFlumazenilGABA ModulatorsGamma-Aminobutyric AcidHumansMaleModels, NeurologicalPerceptual DisordersPiperazinesPsychoses, Substance-InducedReceptors, GABA-AReceptors, Serotonin, 5-HT2Reference ValuesSerotoninSerotonin Receptor Agonists